ABSTRACT
BACKGROUND: Ovarian granulosa cell tumors (GCT) are usually treated by surgery and chemotherapy. Successful response to GnRH agonists as an adjuvant therapy has previously been reported. In this case of recurrent GCT, we used a GnRH antagonist. CASE: A 78-year-old woman underwent surgery for an ovarian granulosa cell tumor (pT1a N0 Mx). Six months later, laparotomy revealed an inoperable recurrence of the tumor. Experimental treatment with a GnRH antagonist was not clearly successful. This is in contrast to the previously proven benefit of GnRH agonist therapy in this type of malignancy and to the positive response elicited by GnRH antagonists in epithelial ovarian tumors. CONCLUSION: GnRH antagonist therapy had no demonstrable efficacy in the treatment of a poorly differentiated and aggressive recurrent granulosa cell tumor.
Subject(s)
Gonadotropin-Releasing Hormone/analogs & derivatives , Gonadotropin-Releasing Hormone/antagonists & inhibitors , Granulosa Cell Tumor/drug therapy , Ovarian Neoplasms/drug therapy , Aged , Chemotherapy, Adjuvant , Female , Gonadotropin-Releasing Hormone/therapeutic use , Granulosa Cell Tumor/surgery , Humans , Neoplasm Recurrence, Local/drug therapy , Ovarian Neoplasms/surgeryABSTRACT
In a double-blind trial in 60 children suffering from gastroenteritis complicated by vomiting, it was found that suppositories of domperidone (30 mg) were more effective than either metoclopramide (10 mg) or placebo in reducing the severity of vomiting, nausea and other symptomatic parameters. No side effects were reported throughout the 24 hour period of the trial and the results suggest that domperidone suppositories may well prove to be the drug of choice in such cases of paediatric vomiting.
Subject(s)
Antiemetics/therapeutic use , Benzimidazoles/therapeutic use , Metoclopramide/therapeutic use , Nausea/drug therapy , Piperidines/therapeutic use , Vomiting/drug therapy , Antiemetics/administration & dosage , Child , Child, Preschool , Clinical Trials as Topic , Double-Blind Method , Female , Gastroenteritis/complications , Humans , Male , SuppositoriesABSTRACT
Forty-seven infants and children suffering from chronic vomiting or regurgitation, participated in a two-week double-blind trial comparing 1% drops of domperidone, 1% metoclopramide drops or placebo. The dose was 0.3 mg/kg given t.d.s. before meals. Both active medicaments were significantly more effective than placebo in controlling the symptoms and domperidone was also significantly superior to metoclopramide. It is concluded, in view of the good safety margin with domperidone, that this drug could become the treatment of choice in such cases.
